title: Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.
abstract: A study in Chinese patients with chronic hepatitis B showed that treatment with lamivudine for 1 year significantly improves liver histology and enhances hepatitis B e antigen (HBeAg) seroconversion compared with placebo. Fifty-eight patients from this 1-year study have received long-term treatment with lamivudine 100 mg; the outcome of 3 years of lamivudine is reported here. Before treatment, all patients had detectable HBeAg. HBeAg seroconversion (HBeAg-negative, anti-HBe-positive), hepatitis B virus (HBV)-DNA suppression, alanine transaminase (ALT) normalization, emergence of YMDD variant HBV, liver histology, and long-term safety were assessed. After 3 years of continuous treatment with lamivudine 100 mg daily, 40% (23 of 58) of patients achieved HBeAg seroconversion. In patients with baseline serum ALT >2 x upper limit of normal (ULN), the rate of HBeAg seroconversion was 65% (17 of 26). Median serum HBV-DNA concentrations were below the level of detection, and median ALT concentrations were within the normal range throughout 3 years of treatment. YMDD variant HBV emerged in 33 of 58 (57%) patients during the 3 years, of whom 9 (27%) achieved HBeAg seroconversion (6 after emergence of YMDD variant HBV). ALT levels and histologic scores after emergence of YMDD variant HBV did not show major deterioration. Lamivudine was well tolerated during 3 years of therapy. In conclusion, these data in Chinese patients with chronic hepatitis B show enhanced seroconversion rates with extended lamivudine treatment. Up to two thirds of patients with moderately elevated pretreatment ALT achieved HBeAg seroconversion after 3 years of therapy.
authors.affiliation: Department of Medicine and Therapeutics, Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong. nancyleung@cuhk.edu.hk
authors.forename: N W
authors.initials: NW
authors.lastname: Leung
authors.forename: C L
authors.initials: CL
authors.lastname: Lai
authors.forename: T T
authors.initials: TT
authors.lastname: Chang
authors.forename: R
authors.initials: R
authors.lastname: Guan
authors.forename: C M
authors.initials: CM
authors.lastname: Lee
authors.forename: K Y
authors.initials: KY
authors.lastname: Ng
authors.forename: S G
authors.initials: SG
authors.lastname: Lim
authors.forename: P C
authors.initials: PC
authors.lastname: Wu
authors.forename: J C
authors.initials: JC
authors.lastname: Dent
authors.forename: S
authors.initials: S
authors.lastname: Edmundson
authors.forename: L D
authors.initials: LD
authors.lastname: Condreay
authors.forename: R N
authors.initials: RN
authors.lastname: Chien
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D004279:DNA, Viral / Q000097:blood; D003692:Delayed-Action Preparations; D005260:Female; D014644:Genetic Variation / Q000502:physiology; D006513:Hepatitis B e Antigens / Q000032:analysis*; D006515:Hepatitis B virus / Q000235:genetics; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology / Q000821:virology; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D008099:Liver / Q000473:pathology; D008297:Male; D008875:Middle Aged; D012449:Safety; D013997:Time Factors
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D003692:Delayed-Action Preparations; D006513:Hepatitis B e Antigens; D019259:Lamivudine; D000410:Alanine Transaminase